{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:37:35Z","timestamp":1787240255707,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":102,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032211064","type":"print"},{"value":"9783032211071","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Classic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and 5-methoxy-dimethyltryptamine (5-MeO-DMT) have shown promising effects in the treatment of certain mental health conditions. Enthusiastic claims about their therapeutic potential have led to overly optimistic reactions in the media and the public, subsequently resulting in increased use outside of clinical contexts and a heightened rate of psychedelic-related complications. As psychedelics exhibit low toxicity and hardly any habit-forming potential, the typical risks and harms of these substances are often overlooked by mental health professionals and under-assessed in psychedelic research. Similar to the medical history of other psychoactive substances introduced as medicines such as opioids, cocaine, and benzodiazepines, awareness for psychedelic-related complications has emerged with delay. Psychedelics are characterized by a wide range of acute effects on the human psyche and by a particular temporal dynamic in which these effects unfold, including acute, subacute, and long-term effects. Knowledge of how psychedelic effects unfold is not only essential for their use in therapy but also for the understanding and management of risks and complications.<\/jats:p>\n                  <jats:p>Here we provide an overview of complications that may be associated with the use of classic psychedelics, drawing on historical and current classification approaches and using the typical temporal dynamics of drug effects as a guiding thread. We will also discuss to what extent psychedelic-related disorders can be causally and specifically attributed to psychedelic use. Finally, considerations regarding the placement of psychedelic-related disorders within nosological-diagnostic classification systems will be discussed. The increasing interest in using psychedelics within the framework of psychotherapy and the rise of non-medical use underscore the need for a more nuanced classification of psychedelic-related risks and harms. The suggested classification can be used as a comprehensive starting point for the assessment of psychedelic-related complications, contributing to maximizing benefits and minimizing risks of these substances in research, therapy, and beyond.<\/jats:p>","DOI":"10.1007\/7854_2026_614","type":"book-chapter","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:00:57Z","timestamp":1772132457000},"page":"127-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Classifying Psychedelic-Related Complications"],"prefix":"10.1007","author":[{"given":"Tomislav","family":"Maji\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euphrosyne","family":"Gouzoulis-Mayfrank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"8","key":"614_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/archpsyc.1983.01790070074009","volume":"40","author":"HD Abraham","year":"1983","unstructured":"Abraham HD (1983) Visual phenomenology of the LSD flashback. Arch Gen Psychiatry 40(8):884. https:\/\/doi.org\/10.1001\/archpsyc.1983.01790070074009","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"614_CR2","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/j.1360-0443.1993.tb02018.x","volume":"88","author":"HD Abraham","year":"1993","unstructured":"Abraham HD, Aldridge AM (1993) Adverse consequences of lysergic acid diethylamide. Addiction 88(10):1327\u20131334. https:\/\/doi.org\/10.1111\/j.1360-0443.1993.tb02018.x","journal-title":"Addiction"},{"key":"614_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2025_608","volume-title":"Curr Topics Behav Neurosci","author":"HD Aicher","year":"2025","unstructured":"Aicher HD, R\u00f6skamp A, Moser M, Brand M (2025) The role and ethics of touch and non-touch in psychedelic-assisted therapy. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2025_608"},{"key":"614_CR4","volume-title":"Psychedelic integration: psychotherapy for non-ordinary states of consciousness (First edition)","author":"M Aixal\u00e0","year":"2022","unstructured":"Aixal\u00e0 M (2022) Psychedelic integration: psychotherapy for non-ordinary states of consciousness (First edition). Synergetic Press"},{"key":"614_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2024_532","volume-title":"Curr Topics Behav Neurosci","author":"M Aixal\u00e0","year":"2024","unstructured":"Aixal\u00e0 M (2024) Deepening psychedelic integration: exploring complex settings, understanding user\u2019s struggles, and implementing safe interventions. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2024_532"},{"key":"614_CR6000","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association (APA) (2000) Diagnostic and statistical manual of mental disorders (4th ed., text rev.). https:\/\/doi.org\/10.1176\/appi.books.9780890423349","DOI":"10.1176\/appi.books.9780890423349"},{"key":"614_CR6","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-5-TR)","author":"American Psychiatric Association (APA)","year":"2022","unstructured":"American Psychiatric Association (APA) (2022) Diagnostic and statistical manual of mental disorders (DSM-5-TR). American Psychiatric Association Publishing. https:\/\/doi.org\/10.1176\/appi.books.9780890425787"},{"key":"614_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2025_609","volume-title":"Curr Topics Behav Neurosci","author":"EK Argyri","year":"2025","unstructured":"Argyri EK, Evans J (2025) Ontologically challenging psychedelic experiences: considerations for managing associated distress. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2025_609"},{"issue":"2","key":"614_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11673-024-10386-4","volume":"22","author":"M Barber","year":"2025","unstructured":"Barber M, Gardner J, Carter A (2025) History, hype, and responsible psychedelic medicine: a qualitative study of psychedelic researchers. J Bioethical Inq 22(2):327\u2013343. https:\/\/doi.org\/10.1007\/s11673-024-10386-4","journal-title":"J Bioethical Inq"},{"issue":"12","key":"614_CR9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","volume":"30","author":"FS Barrett","year":"2016","unstructured":"Barrett FS, Bradstreet MP, Leoutsakos J-MS, Johnson MW, Griffiths RR (2016) The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 30(12):1279\u20131295. https:\/\/doi.org\/10.1177\/0269881116678781","journal-title":"J Psychopharmacol"},{"key":"614_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2025_600","volume-title":"Curr Topics Behav Neurosci","author":"LA Basedow","year":"2025","unstructured":"Basedow LA, Riemer TG (2025) Acute effects and long-term neuropsychological consequences of classic psychedelics use. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2025_600"},{"issue":"10","key":"614_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O\u2019Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L (2022) Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 79(10):953. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096","journal-title":"JAMA Psychiatry"},{"key":"614_CR12","first-page":"1","volume":"37","author":"K Bonhoeffer","year":"1917","unstructured":"Bonhoeffer K (1917) Die exogenen Reaktionstypen. Z Gesamte Neurol Psychiatr 37:1\u201347","journal-title":"Z Gesamte Neurol Psychiatr"},{"key":"614_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2024_559","volume-title":"Curr Topics Behav Neurosci","author":"MM Bradberry","year":"2024","unstructured":"Bradberry MM, Appelbaum PS, Gukasyan N (2024) Informed consent in psychedelic-assisted therapy. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2024_559"},{"issue":"1","key":"614_CR14","doi-asserted-by":"publisher","first-page":"15998","DOI":"10.1038\/s41598-023-41145-x","volume":"13","author":"R Bremler","year":"2023","unstructured":"Bremler R, Katati N, Shergill P, Erritzoe D, Carhart-Harris RL (2023) Case analysis of long-term negative psychological responses to psychedelics. Sci Rep 13(1):15998. https:\/\/doi.org\/10.1038\/s41598-023-41145-x","journal-title":"Sci Rep"},{"key":"614_CR1500","doi-asserted-by":"publisher","unstructured":"Br\u00f6cker AL, Maji\u0107 T, Montag C (2026) Psychedelic-Related Psychosis: From Model Psychosis to Psycyhotherapy. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2026_613","DOI":"10.1007\/7854_2026_613"},{"key":"614_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2025_579","volume-title":"Curr Topics Behav Neurosci","author":"AE Calder","year":"2025","unstructured":"Calder AE, Diehl VJ, Hasler G (2025) Traumatic psychedelic experiences. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2025_579"},{"key":"614_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jad.2024.08.091","volume":"365","author":"AE Calder","year":"2024","unstructured":"Calder AE, Hasler G (2024) Validation of the Swiss psychedelic side effects inventory: standardized assessment of adverse effects in studies of psychedelics and MDMA. J Affect Disord 365:258\u2013264. https:\/\/doi.org\/10.1016\/j.jad.2024.08.091","journal-title":"J Affect Disord"},{"key":"614_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2024_531","volume-title":"Curr Topics Behav Neurosci","author":"C Caporuscio","year":"2024","unstructured":"Caporuscio C, Fink SB (2024) Epistemic risk reduction in psychedelic-assisted therapy. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2024_531"},{"key":"614_CR18","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291725101761","volume":"55","author":"C Caporuscio","year":"2025","unstructured":"Caporuscio C, Poppe C, Gieselmann A, Repantis D (2025) Ethical issues with psychedelic-assisted treatments in psychiatry: a systematic scoping review. Psychol Med 55:e284. https:\/\/doi.org\/10.1017\/S0033291725101761","journal-title":"Psychol Med"},{"issue":"2","key":"614_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/1874473708666150107115515","volume":"7","author":"M Carvalho","year":"2015","unstructured":"Carvalho M, De Sousa M, Frango P, Dias P, Carvalho J, Rodrigues M, Rodrigues T (2015) Crisis intervention related to the use of psychoactive substances in recreational settings \u2013 evaluating the Kosmicare project at boom festival. Curr Drug Abuse Rev 7(2):81\u2013100. https:\/\/doi.org\/10.2174\/1874473708666150107115515","journal-title":"Curr Drug Abuse Rev"},{"issue":"1","key":"614_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/15265161.2024.2433421","volume":"25","author":"K Cheung","year":"2025","unstructured":"Cheung K, Earp BD, Patch K, Yaden DB (2025) Distinctive but not exceptional: the risks of psychedelic ethical exceptionalism. Am J Bioeth 25(1):16\u201328. https:\/\/doi.org\/10.1080\/15265161.2024.2433421","journal-title":"Am J Bioeth"},{"issue":"1","key":"614_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/15265161.2025.2434398","volume":"25","author":"IG Cohen","year":"2025","unstructured":"Cohen IG, Marks M (2025) Psychedelic medicine exceptionalism. Am J Bioeth 25(1):6\u201315. https:\/\/doi.org\/10.1080\/15265161.2025.2434398","journal-title":"Am J Bioeth"},{"issue":"2","key":"614_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/jama.1962.03050280091013b","volume":"181","author":"S Cohen","year":"1962","unstructured":"Cohen S (1962) Complications associated with lysergic acid diethylamide (LSD-25). JAMA 181(2):161. https:\/\/doi.org\/10.1001\/jama.1962.03050280091013b","journal-title":"JAMA"},{"issue":"5","key":"614_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1001\/archpsyc.1963.01720110051006","volume":"8","author":"S Cohen","year":"1963","unstructured":"Cohen S (1963) Prolonged adverse reactions to lysergic acid diethylamide. Arch Gen Psychiatry 8(5):475. https:\/\/doi.org\/10.1001\/archpsyc.1963.01720110051006","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"614_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0033-3182(66)72149-5","volume":"7","author":"S Cohen","year":"1966","unstructured":"Cohen S (1966) A Classification of LSD complications. Psychosomatics 7(3):182\u2013186. https:\/\/doi.org\/10.1016\/S0033-3182(66)72149-5","journal-title":"Psychosomatics"},{"issue":"4","key":"614_CR25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/02791072.1985.10524333","volume":"17","author":"S Cohen","year":"1985","unstructured":"Cohen S (1985) LSD: the varieties of psychotic experience. J Psychoactive Drugs 17(4):291\u2013296. https:\/\/doi.org\/10.1080\/02791072.1985.10524333","journal-title":"J Psychoactive Drugs"},{"key":"614_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2024_562","volume-title":"Curr Topics Behav Neurosci","author":"C Costines","year":"2024","unstructured":"Costines C, Schmidt TT (2024) Phenomenology of psychedelic experiences and psychedelic-associated distressing effects: quantifying subjective experiences. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2024_562"},{"issue":"S 2","key":"614_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1055\/s-2007-979351","volume":"31","author":"A Dittrich","year":"1998","unstructured":"Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(S 2):80\u201384. https:\/\/doi.org\/10.1055\/s-2007-979351","journal-title":"Pharmacopsychiatry"},{"key":"614_CR28","doi-asserted-by":"publisher","DOI":"10.1353\/book.3470","volume-title":"Psychedelic psychiatry: LSD from clinic to campus","author":"E Dyck","year":"2008","unstructured":"Dyck E (2008) Psychedelic psychiatry: LSD from clinic to campus. Johns Hopkins University Press"},{"key":"614_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2024_511","volume-title":"Curr Topics Behav Neurosci","author":"E Dyck","year":"2024","unstructured":"Dyck E, Dixon J (2024) Completing the circle: a history of psychedelics and harm reduction. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2024_511"},{"issue":"2","key":"614_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1086\/707512","volume":"34","author":"E Dyck","year":"2020","unstructured":"Dyck E, Elcock C (2020) Reframing bummer trips: scientific and cultural explanations to adverse reactions to psychedelic drug use. Soc Hist Alcohol Drugs 34(2):271\u2013296. https:\/\/doi.org\/10.1086\/707512","journal-title":"Soc Hist Alcohol Drugs"},{"key":"614_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2024_535","volume-title":"Curr Topics Behav Neurosci","author":"J Evans","year":"2024","unstructured":"Evans J, Adams JH (2024) Guruism and cultic social dynamics in psychedelic practices and organisations. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2024_535"},{"issue":"1","key":"614_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1176\/appi.prcp.20240128","volume":"7","author":"J Evans","year":"2025","unstructured":"Evans J, Aixal\u00e0 M, Anderson BT, Brennan W, Bremler R, Breeksema JJ, Burback L, Calder AE, Carhart-Harris RL, Cheung K, Devenot N, Gorman I, Gre\u0144 J, Hendricks PS, Holoyda B, Jacobs E, Kreck\u00e9 J, Kruger DJ, Luke D et al (2025) On minimizing risk and harm in the use of psychedelics. Psychiatr Res Clin Pract 7(1):4\u20138. https:\/\/doi.org\/10.1176\/appi.prcp.20240128","journal-title":"Psychiatr Res Clin Pract"},{"issue":"10","key":"614_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293349","volume":"18","author":"J Evans","year":"2023","unstructured":"Evans J, Robinson OC, Argyri EK, Suseelan S, Murphy-Beiner A, McAlpine R, Luke D, Michelle K, Prideaux E (2023) Extended difficulties following the use of psychedelic drugs: a mixed methods study. PLoS One 18(10):e0293349. https:\/\/doi.org\/10.1371\/journal.pone.0293349","journal-title":"PLoS One"},{"key":"614_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231172254","volume":"13","author":"R Evens","year":"2023","unstructured":"Evens R, Schmidt ME, Maji\u0107 T, Schmidt TT (2023) The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics. Ther Adv Psychopharmacol 13:204512532311722. https:\/\/doi.org\/10.1177\/20451253231172254","journal-title":"Ther Adv Psychopharmacol"},{"key":"614_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2025_612","volume-title":"Curr Topics Behav Neurosci","author":"R Evens","year":"2025","unstructured":"Evens R, Uyar A, Maji\u0107 T (2025) Managing psychological challenges in the subacute (\u201cafterglow\u201d) window of psychedelic drug effects. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2025_612"},{"key":"614_CR3000","unstructured":"Evens R, Uyar A, Gosslau E, Dambeck F, Repantis D, Wolff M, Lueken U (n.d.) Post-traumatic stress disorder symptoms following psychedelic use: a naturalistic survey study"},{"issue":"7","key":"614_CR36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/0021-9681(70)90054-8","volume":"23","author":"AR Feinstein","year":"1970","unstructured":"Feinstein AR (1970) The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 23(7):455\u2013468. https:\/\/doi.org\/10.1016\/0021-9681(70)90054-8","journal-title":"J Chronic Dis"},{"issue":"8","key":"614_CR37","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1176\/appi.ajp.2010.09020189","volume":"167","author":"DJ Foti","year":"2010","unstructured":"Foti DJ, Kotov R, Guey LT, Bromet EJ (2010) Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 167(8):987\u2013993. https:\/\/doi.org\/10.1176\/appi.ajp.2010.09020189","journal-title":"Am J Psychiatry"},{"key":"614_CR38","volume-title":"Adverse reactions to hallucinogenic drugs, with background papers: conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967","author":"WA Frosch","year":"1969","unstructured":"Frosch WA (1969) Patterns of response to self administration with LSD. In: Meyer RE (ed) Adverse reactions to hallucinogenic drugs, with background papers: conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967. US National Institute of Mental Health"},{"issue":"23","key":"614_CR39","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJM196512022732302","volume":"273","author":"WA Frosch","year":"1965","unstructured":"Frosch WA, Robbins ES, Stern M (1965) Untoward reactions to lysergic acid diethylamide (LSD) resulting in hospitalization. N Engl J Med 273(23):1235\u20131239. https:\/\/doi.org\/10.1056\/NEJM196512022732302","journal-title":"N Engl J Med"},{"issue":"1","key":"614_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1176\/appi.ajp.20230914","volume":"182","author":"S Ghaznavi","year":"2025","unstructured":"Ghaznavi S, Ruskin JN, Haggerty SJ, King F, Rosenbaum JF (2025) Primum non nocere: the onus to characterize the potential harms of psychedelic treatment. Am J Psychiatry 182(1):47\u201353. https:\/\/doi.org\/10.1176\/appi.ajp.20230914","journal-title":"Am J Psychiatry"},{"issue":"16","key":"614_CR41","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1017\/S003329172000389X","volume":"50","author":"SB Goldberg","year":"2020","unstructured":"Goldberg SB, Shechet B, Nicholas CR, Ng CW, Deole G, Chen Z, Raison CL (2020) Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. Psychol Med 50(16):2655\u20132666. https:\/\/doi.org\/10.1017\/S003329172000389X","journal-title":"Psychol Med"},{"issue":"18","key":"614_CR42","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D et al (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 387(18):1637\u20131648. https:\/\/doi.org\/10.1056\/NEJMoa2206443","journal-title":"N Engl J Med"},{"issue":"6","key":"614_CR43","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"R Griffiths","year":"2008","unstructured":"Griffiths R, Richards W, Johnson M, McCann U, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22(6):621\u2013632. https:\/\/doi.org\/10.1177\/0269881108094300","journal-title":"J Psychopharmacol"},{"key":"614_CR44","volume-title":"LSD psychotherapy","author":"S Grof","year":"2001","unstructured":"Grof S (2001) LSD psychotherapy, 3rd edn. Multidisciplinary Association for Psychedelic Studies","edition":"3"},{"key":"614_CR45","volume-title":"Realms of the human unconscious: observations from LSD research","author":"S Grof","year":"2016","unstructured":"Grof S (2016) Realms of the human unconscious: observations from LSD research. Souvenir Press"},{"issue":"3","key":"614_CR46","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","volume":"61","author":"AL Halberstadt","year":"2011","unstructured":"Halberstadt AL, Geyer MA (2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61(3):364\u2013381. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.01.017","journal-title":"Neuropharmacology"},{"issue":"12","key":"614_CR47","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn I (2016) Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol 30(12):1259\u20131267. https:\/\/doi.org\/10.1177\/0269881116677852","journal-title":"J Psychopharmacol"},{"key":"614_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2024_509","volume-title":"Curr Topics Behav Neurosci","author":"I Hartogsohn","year":"2024","unstructured":"Hartogsohn I (2024) Set and setting for psychedelic harm reduction. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2024_509"},{"key":"614_CR49","volume-title":"Pilot who tried to shut off engines says he was hallucinating on mushrooms","author":"E Helmore","year":"2023","unstructured":"Helmore E (2023) Pilot who tried to shut off engines says he was hallucinating on mushrooms. Guardian"},{"key":"614_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2025_606","volume-title":"Curr Topics Behav Neurosci","author":"T Hirschfeld","year":"2025","unstructured":"Hirschfeld T, Blei F, Stegemann L, Van Der Gouwe D, Smit-Rigter L (2025) Psychedelic drug checking: analytical and strategic challenges in harm reduction for classic psychedelics. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2025_606"},{"issue":"11","key":"614_CR51","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41386-023-01588-2","volume":"48","author":"T Hirschfeld","year":"2023","unstructured":"Hirschfeld T, Prugger J, Maji\u0107 T, Schmidt TT (2023) Dose-response relationships of LSD-induced subjective experiences in humans. Neuropsychopharmacology 48(11):1602\u20131611. https:\/\/doi.org\/10.1038\/s41386-023-01588-2","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"614_CR52","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/0269881121992676","volume":"35","author":"T Hirschfeld","year":"2021","unstructured":"Hirschfeld T, Schmidt TT (2021) Dose\u2013response relationships of psilocybin-induced subjective experiences in humans. J Psychopharmacol 35(4):384\u2013397. https:\/\/doi.org\/10.1177\/0269881121992676","journal-title":"J Psychopharmacol"},{"issue":"3","key":"614_CR53","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40429-021-00385-5","volume":"8","author":"T Hirschfeld","year":"2021","unstructured":"Hirschfeld T, Smit-Rigter L, van der Gouwe D, Reiche S, St\u00f6ver H, Maji\u0107 T (2021) Safer tripping: serotonergic psychedelics and drug checking. Submission and detection rates, potential harms, and challenges for drug analysis. Curr Addict Rep 8(3):389\u2013398. https:\/\/doi.org\/10.1007\/s40429-021-00385-5","journal-title":"Curr Addict Rep"},{"key":"614_CR54","volume-title":"Flashback-Ph\u00e4nomene als Nachwirkung von Halluzinogeneinnahme: Eine kritische Untersuchung zu klinischen und \u00e4tiologischen Aspekten","author":"D Holland","year":"2011","unstructured":"Holland D, Passie T, Halpern JH (2011) Flashback-Ph\u00e4nomene als Nachwirkung von Halluzinogeneinnahme: Eine kritische Untersuchung zu klinischen und \u00e4tiologischen Aspekten. VWB, Verlag f\u00fcr Wissenschaft und Bildung"},{"key":"614_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2024_529","volume-title":"Curr Topics Behav Neurosci","author":"X Hu","year":"2024","unstructured":"Hu X, Gorman I, Nielson E (2024) Psychedelic harm reduction and integration: a transtheoretical model for clinical practice. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2024_529"},{"key":"614_CR56","doi-asserted-by":"publisher","unstructured":"Hutchison KE, Hooper JF, Karoly HC (2025) Psilocybin outside the clinic: public health challenges of increasing publicity, accessibility, and use. JAMA Psychiatr. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.3038","DOI":"10.1001\/jamapsychiatry.2025.3038"},{"issue":"6","key":"614_CR57","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1024\/0939-5911\/a000959","volume":"71","author":"D Jalilzadeh Masah","year":"2025","unstructured":"Jalilzadeh Masah D, Marbin D, Maji\u0107 T (2025) Three cases of depersonalization\/Derealization disorder related to the use of classic psychedelics. SUCHT 71(6):353\u2013360. https:\/\/doi.org\/10.1024\/0939-5911\/a000959","journal-title":"SUCHT"},{"key":"614_CR58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/bs.irn.2015.01.001","volume-title":"International review of neurobiology","author":"M Jay","year":"2015","unstructured":"Jay M (2015) Miracle or Menace? In: International review of neurobiology, vol 120. Elsevier, pp 27\u201339. https:\/\/doi.org\/10.1016\/bs.irn.2015.01.001"},{"key":"614_CR59","unstructured":"J\u00f6bstl L (2025) Between therapy and taboo: a qualitative study on help-seeking experiences in persistent psychedelic-associated psychological symptoms. Unpublished master thesis"},{"key":"614_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2024_515","volume-title":"Curr Topics Behav Neurosci","author":"M Koslowski","year":"2024","unstructured":"Koslowski M, Gasser P (2024) Guiding through challenging psychedelic experiences and \u201cbad trips\u201d. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2024_515"},{"issue":"1","key":"614_CR62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/psymed.2024.0011","volume":"3","author":"DJ Kruger","year":"2025","unstructured":"Kruger DJ, Aday JS, Fields CW, Kolbman N, Glynos N, Barron J, Herberholz M, Boehnke KF (2025) Psychedelic therapist sexual misconduct and other adverse experiences among a sample of naturalistic psychedelic users. Psychedelic Med 3(1):41\u201347. https:\/\/doi.org\/10.1089\/psymed.2024.0011","journal-title":"Psychedelic Med"},{"key":"614_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-86258-8","volume-title":"Die Experimentelle Psychose: Ihre Psychopharmakologie, Ph\u00e4nomenologie und Dynamik in Beziehung Zur Person. Versuch Einer Konditonal-Genetischen und Funktionalen Psychopathologie der Psychose","author":"H Leuner","year":"1962","unstructured":"Leuner H (1962) Die Experimentelle Psychose: Ihre Psychopharmakologie, Ph\u00e4nomenologie und Dynamik in Beziehung Zur Person. Versuch Einer Konditonal-Genetischen und Funktionalen Psychopathologie der Psychose. Springer, Berlin\/Heidelberg"},{"issue":"3","key":"614_CR64","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0269881114568040","volume":"29","author":"T Maji\u0107","year":"2015","unstructured":"Maji\u0107 T, Schmidt TT, Gallinat J (2015) Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol 29(3):241\u2013253. https:\/\/doi.org\/10.1177\/0269881114568040","journal-title":"J Psychopharmacol"},{"issue":"5","key":"614_CR65","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1177\/02698811251326937","volume":"39","author":"T Maji\u0107","year":"2025","unstructured":"Maji\u0107 T, Schmidt TT, Gr\u00f6ticke A, Gasser P, Richards WA, Riemer TG, Evens R (2025) The Afterglow Inventory (AGI): validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics. J Psychopharmacol 39(5):474\u2013488. https:\/\/doi.org\/10.1177\/02698811251326937","journal-title":"J Psychopharmacol"},{"issue":"6","key":"614_CR66","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2025.10847","volume":"11","author":"J Marinis","year":"2025","unstructured":"Marinis J, Clarke ST, Guerin AA, Guastella AJ, Bedi G (2025) Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review. BJPsych Open 11(6):e261. https:\/\/doi.org\/10.1192\/bjo.2025.10847","journal-title":"BJPsych Open"},{"key":"614_CR67","doi-asserted-by":"publisher","unstructured":"Marsden J, Kelleher M, Dunbar F, Ermakova AO, Mitcheson L, Roberts C, Rucker JJ, Scott G, Saeger I, Small F, Seynaeve M (2025) 5-Methoxy- N , N -dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: an open-label, phase 2, proof-of-concept, clinical trial. Addiction add.70260. https:\/\/doi.org\/10.1111\/add.70260","DOI":"10.1111\/add.70260"},{"key":"614_CR68","volume-title":"The varieties of psychedelic experience: the classic guide to the effects of LSD on the human psyche","author":"REL Masters","year":"2000","unstructured":"Masters REL, Houston J (2000) The varieties of psychedelic experience: the classic guide to the effects of LSD on the human psyche. Park Street Press"},{"key":"614_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2025_599","volume-title":"Curr Topics Behav Neurosci","author":"M Michal","year":"2025","unstructured":"Michal M (2025) Psychedelic-associated depersonalization-derealization disorder. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2025_599"},{"issue":"6","key":"614_CR70","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1037\/0022-006X.60.6.845","volume":"60","author":"KT Mueser","year":"1992","unstructured":"Mueser KT, Bellack AS, Blanchard JJ (1992) Comorbidity of schizophrenia and substance abuse: implications for treatment. J Consult Clin Psychol 60(6):845\u2013856. https:\/\/doi.org\/10.1037\/0022-006X.60.6.845","journal-title":"J Consult Clin Psychol"},{"issue":"6","key":"614_CR71","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0306-4603(98)00073-2","volume":"23","author":"KT Mueser","year":"1998","unstructured":"Mueser KT, Drake RE, Wallach MA (1998) Dual diagnosis. Addict Behav 23(6):717\u2013734. https:\/\/doi.org\/10.1016\/S0306-4603(98)00073-2","journal-title":"Addict Behav"},{"issue":"6","key":"614_CR72","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s00213-022-06066-z","volume":"239","author":"F M\u00fcller","year":"2022","unstructured":"M\u00fcller F, Kraus E, Holze F, Becker A, Ley L, Schmid Y, Vizeli P, Liechti ME, Borgwardt S (2022) Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. Psychopharmacology 239(6):1933\u20131943. https:\/\/doi.org\/10.1007\/s00213-022-06066-z","journal-title":"Psychopharmacology"},{"key":"614_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116381","volume":"345","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller F, Sauer T, H\u00e4nny C, M\u00fchlhauser M, Lang UE (2025) Suicide of a patient shortly after psilocybin-assisted psychedelic therapy: a case report. Psychiatry Res 345:116381. https:\/\/doi.org\/10.1016\/j.psychres.2025.116381","journal-title":"Psychiatry Res"},{"issue":"2","key":"614_CR74","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jamapsychiatry.2024.3532","volume":"82","author":"DT Myran","year":"2025","unstructured":"Myran DT, Pugliese M, Xiao J, Kaster TS, Husain MI, Anderson KK, Fabiano N, Wong S, Fiedorowicz JG, Webber C, Tanuseputro P, Solmi M (2025) Emergency department visits involving hallucinogen use and risk of schizophrenia spectrum disorder. JAMA Psychiatry 82(2):142. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.3532","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"614_CR75","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478","journal-title":"Pharmacol Rev"},{"issue":"1","key":"614_CR76","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1086\/383628","volume":"88","author":"SJ Novak","year":"1997","unstructured":"Novak SJ (1997) LSD before Leary: Sidney Cohen\u2019s critique of 1950s psychedelic drug research. Isis 88(1):87\u2013110. https:\/\/doi.org\/10.1086\/383628","journal-title":"Isis"},{"issue":"9752","key":"614_CR77","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","volume":"376","author":"DJ Nutt","year":"2010","unstructured":"Nutt DJ, King LA, Phillips LD (2010) Drug harms in the UK: a multicriteria decision analysis. Lancet 376(9752):1558\u20131565. https:\/\/doi.org\/10.1016\/S0140-6736(10)61462-6","journal-title":"Lancet"},{"key":"614_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1049643","volume":"13","author":"AM Ortiz Bernal","year":"2022","unstructured":"Ortiz Bernal AM, Raison CL, Lancelotta RL, Davis AK (2022) Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: an initial exploratory analysis of the phenomenon\u2019s predictors and its emotional valence. Front Psychiatry 13:1049643. https:\/\/doi.org\/10.3389\/fpsyt.2022.1049643","journal-title":"Front Psychiatry"},{"issue":"11","key":"614_CR79","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","volume":"212","author":"WN Pahnke","year":"1970","unstructured":"Pahnke WN, Kurland AA, Unger S, Savage C, Grof S (1970) The experimental use of psychedelic (LSD) psychotherapy. JAMA 212(11):1856\u20131863","journal-title":"JAMA"},{"key":"614_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2024_533","volume-title":"Curr Topics Behav Neurosci","author":"C Poppe","year":"2024","unstructured":"Poppe C, Repantis D (2024) Ethical aspects of psychedelic-assisted treatments: an overview. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2024_533"},{"issue":"1","key":"614_CR81","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41597-022-01822-4","volume":"9","author":"J Prugger","year":"2022","unstructured":"Prugger J, Derdiyok E, Dinkelacker J, Costines C, Schmidt TT (2022) The altered states database: psychometric data from a systematic literature review. Sci Data 9(1):720. https:\/\/doi.org\/10.1038\/s41597-022-01822-4","journal-title":"Sci Data"},{"issue":"3","key":"614_CR82","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1176\/ajp.124.3.393","volume":"124","author":"E Robbins","year":"1967","unstructured":"Robbins E, Frosch WA, Stern M (1967) Further observations on untoward reactions to LSD. Am J Psychiatry 124(3):393\u2013395. https:\/\/doi.org\/10.1176\/ajp.124.3.393","journal-title":"Am J Psychiatry"},{"issue":"15","key":"614_CR83","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jama.2025.13481","volume":"334","author":"R Robison","year":"2025","unstructured":"Robison R, Barrow R, Conant C, Foster E, Freedman JM, Jacobsen PL, Jemison J, Karas SM, Karlin DR, Solomon TM, Halperin Wernli M, Fava M (2025) Single treatment with MM120 (Lysergide) in generalized anxiety disorder: a randomized clinical trial. JAMA 334(15):1358. https:\/\/doi.org\/10.1001\/jama.2025.13481","journal-title":"JAMA"},{"issue":"431","key":"614_CR84","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1192\/bjp.103.431.332","volume":"103","author":"RA Sandison","year":"1957","unstructured":"Sandison RA, Whitelaw JDA (1957) Further studies in the therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci 103(431):332\u2013343. https:\/\/doi.org\/10.1192\/bjp.103.431.332","journal-title":"J Ment Sci"},{"issue":"2","key":"614_CR85","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/00005053-196802000-00009","volume":"146","author":"CJ Schwarz","year":"1968","unstructured":"Schwarz CJ (1968) The complications of LSD: a review of the literature. J Nerv Ment Dis 146(2):174\u2013186. https:\/\/doi.org\/10.1097\/00005053-196802000-00009","journal-title":"J Nerv Ment Dis"},{"key":"614_CR8000","doi-asserted-by":"publisher","unstructured":"Simeon D, Kozin DS, Segal K, Lerch B (2009) Is depersonalization disorder initiated by illicit drug use any different? A survey of 394 adults. Journal of Clinical Psychiatry, 70(10):1358. https:\/\/doi.org\/10.4088\/JCP.08m04370","DOI":"10.4088\/JCP.08m04370"},{"issue":"7","key":"614_CR86","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00213-023-06478-5","volume":"242","author":"O Simonsson","year":"2025","unstructured":"Simonsson O, Goldberg SB, Chambers R, Osika W, Simonsson C, Hendricks PS (2025a) Psychedelic use and psychiatric risks. Psychopharmacology 242(7):1577\u20131583. https:\/\/doi.org\/10.1007\/s00213-023-06478-5","journal-title":"Psychopharmacology"},{"key":"614_CR87","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291725000716","volume":"55","author":"O Simonsson","year":"2025","unstructured":"Simonsson O, Goldberg SB, Osika W, Stenfors CUD, Chaturvedi S, Swords CM, Narayanan J, Hendricks PS (2025b) Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms. Psychol Med 55:e99. https:\/\/doi.org\/10.1017\/S0033291725000716","journal-title":"Psychol Med"},{"key":"614_CR88","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jad.2023.01.073","volume":"326","author":"O Simonsson","year":"2023","unstructured":"Simonsson O, Hendricks PS, Chambers R, Osika W, Goldberg SB (2023) Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. J Affect Disord 326:105\u2013110. https:\/\/doi.org\/10.1016\/j.jad.2023.01.073","journal-title":"J Affect Disord"},{"issue":"1","key":"614_CR89","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3109\/15563656908990915","volume":"2","author":"DE Smith","year":"1969","unstructured":"Smith DE (1969) LSD and the psychedelic syndrome. Clin Toxicol 2(1):69\u201373. https:\/\/doi.org\/10.3109\/15563656908990915","journal-title":"Clin Toxicol"},{"issue":"10","key":"614_CR90","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/00005053-198410000-00001","volume":"172","author":"RJ Strassman","year":"1984","unstructured":"Strassman RJ (1984) Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis 172(10):577\u2013595. https:\/\/doi.org\/10.1097\/00005053-198410000-00001","journal-title":"J Nerv Ment Dis"},{"issue":"11","key":"614_CR91","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0269881110382466","volume":"25","author":"E Studerus","year":"2011","unstructured":"Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25(11):1434\u20131452. https:\/\/doi.org\/10.1177\/0269881110382466","journal-title":"J Psychopharmacol"},{"issue":"6","key":"614_CR92","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1001\/jama.1966.03110060063015","volume":"197","author":"JT Ungerleider","year":"1966","unstructured":"Ungerleider JT (1966) The dangers of LSD: analysis of seven months\u2019 experience in a university hospital\u2019s psychiatric service. JAMA 197(6):389. https:\/\/doi.org\/10.1001\/jama.1966.03110060063015","journal-title":"JAMA"},{"issue":"1","key":"614_CR93","first-page":"49","volume":"106","author":"JT Ungerleider","year":"1967","unstructured":"Ungerleider JT, Fisher DD (1967) The problems of LSD-25 and emotional disorder. Calif Med 106(1):49\u201355","journal-title":"Calif Med"},{"key":"614_CR94","doi-asserted-by":"publisher","unstructured":"Vardy MM, Kay SR (1983) LSD psychosis or LSD-induced schizophrenia?: a multimethod inquiry. Arch Gen Psychiatry 40(8):877\u2013883. https:\/\/doi.org\/10.1001\/archpsyc.1983.01790070067008","DOI":"10.1001\/archpsyc.1983.01790070067008"},{"key":"614_CR95","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2024_534","volume-title":"Curr Topics Behav Neurosci","author":"G Viljoen","year":"2024","unstructured":"Viljoen G, Betzler F (2024) Anxiety and affective symptoms related to the use of classic psychedelics: a systematic review. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2024_534"},{"key":"614_CR96","unstructured":"World Health Organization (2022) ICD-11: international classification of diseases (11th revision). https:\/\/icd.who.int\/"},{"key":"614_CR97","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fnins.2020.00078","volume":"14","author":"JB Zawilska","year":"2020","unstructured":"Zawilska JB, Kacela M, Adamowicz P (2020) NBOMes\u2013highly potent and toxic alternatives of LSD. Front Neurosci 14:78. https:\/\/doi.org\/10.3389\/fnins.2020.00078","journal-title":"Front Neurosci"},{"key":"614_CR98","volume-title":"Drug, set, and setting: the basis for controlled intoxicant use","author":"NE Zinberg","year":"1986","unstructured":"Zinberg NE (1986) Drug, set, and setting: the basis for controlled intoxicant use. Yale University Press"},{"key":"614_CR99","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2025_610","volume-title":"Curr Topics Behav Neurosci","author":"MF \u017duljevi\u0107","year":"2025","unstructured":"\u017duljevi\u0107 MF, Maji\u0107 T (2025) Flashbacks, hallucinogen persisting perception disorder (HPPD), and reactivations following the use of classic psychedelics: classification and therapeutic management. In: Curr Topics Behav Neurosci. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/7854_2025_610"}],"container-title":["Current Topics in Behavioral Neurosciences","Psychedelic Harm Reduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2026_614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:42:26Z","timestamp":1777880546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2026_614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032211064","9783032211071"],"references-count":102,"URL":"https:\/\/doi.org\/10.1007\/7854_2026_614","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"25 February 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}